Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA REMS Platform Will Make Safety Plans Easy – Maybe Too Easy?

This article was originally published in The Pink Sheet Daily

Executive Summary

There is concern that common software package could mean more drugs end up with risk management programs.

Advertisement

Related Content

REMS Standardization Could Help Opioid Education Efforts
PDUFA VI: BIO Survey Finds FDA Communication Problems
FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
MedGuide-Only REMS Will Be The Exception, Not The Norm, As FDA Relaxes Policy

Topics

Advertisement
UsernamePublicRestriction

Register

PS077963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel